View Archive »
About The Cover
The cover for the November issue of Oncotarget was taken from a series of images showing the effects of miR-98 on cell activities. Pictured above is the GFP expression of anti-miR-98 cells. See Siragam et al.
|
|
Table of Contents
Editorial
|
| Tolllike receptor 2: therapeutic target for gastric carcinogenesis |
|
https://doi.org/10.18632/oncotarget.735
|
| 1260-1261 |
|
| KRAS above and beyond – EGFR in pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.750
|
| 1262-1263 |
|
| Epigenetics cMyc and Aggressive Bcell Lymphomas |
|
https://doi.org/10.18632/oncotarget.748
|
| 1264-1265 |
|
| Genetic Induction of the Warburg Effect Inhibits Tumor Growth |
|
https://doi.org/10.18632/oncotarget.739
|
| 1266-1267 |
|
| miR150: targeting MLL leukemia |
|
https://doi.org/10.18632/oncotarget.736
|
| 1268-1269 |
|
| Immunosurveillance against cancerassociated hyperploidy |
|
https://doi.org/10.18632/oncotarget.753
|
| 1270-1271 |
Reviews
|
| NRF2 and p53: Januses in cancer |
|
https://doi.org/10.18632/oncotarget.754
|
| 1272-1283 |
|
| Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia |
|
https://doi.org/10.18632/oncotarget.749
|
| 1284-1293 |
Research Perspectives
|
| Identification of acetylationdependent regulatory mechanisms that govern the oncogenic functions of Skp2 |
|
https://doi.org/10.18632/oncotarget.740
|
| 1294-1300 |
|
| The Interfaces Between Signal Transduction Pathways: IGF1/mTor p53 and the Parkinson Disease Pathway |
|
https://doi.org/10.18632/oncotarget.759
|
| 1301-1307 |
Research Papers
|
| Recurrent targets of aberrant somatic hypermutation in lymphoma |
|
https://doi.org/10.18632/oncotarget.653
|
| 1308-1319 |
|
| Genes affected by mouse mammary tumor virus MMTV proviral insertions in mouse mammary tumors are deregulated or mutated in primary human mammary tumors |
|
https://doi.org/10.18632/oncotarget.682
|
| 1320-1334 |
|
| Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation Highlight of a putative therapeutic window in Multiple Myeloma |
|
https://doi.org/10.18632/oncotarget.650
|
| 1335-1347 |
|
| Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN |
|
https://doi.org/10.18632/oncotarget.694
|
| 1348-1355 |
|
| Pyruvate kinase is a dosagedependent regulator of cellular amino acid homeostasis |
|
https://doi.org/10.18632/oncotarget.730
|
| 1356-1369 |
|
| MicroRNA miR98 inhibits tumor angiogenesis and invasion by targeting activin receptorlike kinase4 and matrix metalloproteinase11 |
|
https://doi.org/10.18632/oncotarget.717
|
| 1370-1385 |
|
| Tumor suppressive microRNA218 inhibits cancer cell migration and invasion through targeting laminin332 in head and neck squamous cell carcinoma |
|
https://doi.org/10.18632/oncotarget.709
|
| 1386-1400 |
|
| Targeting MCT1 oncogene inhibits Shc pathway and xenograft tumorigenicity |
|
https://doi.org/10.18632/oncotarget.688
|
| 1401-1415 |
|
| Superior efficacy of cotreatment with dual PI3K/mTOR inhibitor NVPBEZ235 and panhistone deacetylase inhibitor against human pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.724
|
| 1416-1427 |
|
| Association study of nicotinic acetylcholine receptor genes identifies a novel lung cancer susceptibility locus near CHRNA1 in AfricanAmericans |
|
https://doi.org/10.18632/oncotarget.746
|
| 1428-1438 |
|
| Epigenetic Regulation of miRNA211 by MMP9 Governs Glioma Cell Apoptosis Chemosensitivity and Radiosensitivity |
|
https://doi.org/10.18632/oncotarget.683
|
| 1439-1454 |
|
| Identification of miR30d as a novel prognostic maker of prostate cancer |
|
https://doi.org/10.18632/oncotarget.696
|
| 1455-1471 |
|
| Targeting HIF2α Translation with Tempol in VHLDeficient Clear Cell Renal Cell Carcinoma |
|
https://doi.org/10.18632/oncotarget.561
|
| 1472-1482 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
